ocrelizumab,natalizumab,fingolimod
Roche,biogen,Novartis
['ease', '#ms ', 'ocrelizumab', 'modify', 'achieve,(-u achieve),(-u-achieve),(-uachieve)', 'neda']
#ectrims2022
in real-world settings, relapsing #ms patients on #ocrelizumab achieved 28% greater neda-3 rates compared to ones treated with other disease-modifying agents
#visualabstract 
Here, is the CLINICAL TRIAL OF THE DAY 
The interesting clinical study with impact on future clinical practice 
// Our editor's opinion only //